Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    Nurse well-being
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    November 23, 2023
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    Oncology nurse education
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    November 10, 2023
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    Oncology nurse influence
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    November 03, 2023
    Filipino American History Month nurse standing next to flag
    Nurse empowerment
    Filipino American History Month Shines Light on the Contributions and Challenges of a Committed Community of Nurses
    October 16, 2023
    Explore Somatic Biomarker Testing Report Component Biomarker Testing
    Clinical practice
    Learn How to Read a Somatic Biomarker Testing Report
    October 06, 2023
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Clinical practice

    Researcher Reflects on How Cancer Was Reported on in the Mid-20th Century
    Research

    Researcher Reflects on How Cancer Was Reported on in the Mid-20th Century

    Our understanding of cancer has come a great ways over the past few decades, and some of the progress can be traced back to the 1950’s film Challenge: Science Against Cancer, explained David Cantor, PhD, researcher at the Instituto de Desarrollo Económico y Social, Buenos Aires Argentina, adjunct professor in the School of Public Health at the University of Maryland, College Park, in a July 2022 essay for the National Library of Medicine.

    October 19, 2022
    Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer
    Sexual/reproductive issues

    Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer

    Sexual dysfunction is one of the most common side effects of cancer treatment, yet oncology professionals often under address patients’ sexuality and sexual dysfunction concerns. Providers cite lack of time, training, and resources as barriers to initiating important discussions about sexual side effects, and studies show that patients’ age and prognosis are additional hindering factors.

    October 18, 2022
    Nurses Have Immediate Access to Necessary Medications and Supplies With Hypersensitivity Reaction Kits
    Oncologic emergencies

    Nurses Have Immediate Access to Necessary Medications and Supplies With Hypersensitivity Reaction Kits

    Biologic agents or chemotherapies can trigger hypersensitivity reactions, which occur when a patient’s immune system identifies an agent as an antigen and initiates a complex reaction involving sensitization of T lymphocytes and macrophages, production of antibodies, and release of histamine. Developing and implementing a hypersensitivity kit containing all necessary medications and associated protocols allows nurses to immediately implement management when reactions occur.

    October 13, 2022
    Understand Genomic Variants to Confidently Educate Your Patients
    Genetics & genomics

    Understand Genomic Variants to Confidently Educate Your Patients

    Nurses’ consistent and correct use of genomics terminology is critical to reduce confusion and provide safe genomics care to patients and their families, especially when explaining the meaning of genomic tests or findings.

    October 13, 2022
    Precision Oncology Models Guide Tailored Nursing Interventions for Ovarian Cancer Symptom Clusters
    Ovarian cancer

    Precision Oncology Models Guide Tailored Nursing Interventions for Ovarian Cancer Symptom Clusters

    Using the National Institutes of Health Symptom Science Model and Nursing Science Precision Health Model helps oncology nurses to recognize symptoms more promptly in patients with ovarian cancer and provide precision interventions that address racial disparities and foster equity in symptom-focused, patient-centered care, Mahoney and Pierce reported in the October 2022 issue of the Clinical Journal of Oncology Nursing.

    October 11, 2022
    What Is HER2-Low Breast Cancer?
    Breast cancer

    What Is HER2-Low Breast Cancer?

    Human epidermal growth factor receptor 2 (HER2) proteins are involved in normal cellular growth and are found on the surface of all breast cells. Approximately 20% of breast cancers are HER2 positive, meaning they have high levels of HER2 protein, and those cancers typically grow and metastasize more quickly than other types of breast cancer.

    October 07, 2022
    Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki
    Clinical practice

    Oncology Drug Reference Sheet: Fam-Trastuzumab Deruxtecan-Nxki

    Bringing the first agent to market for the indication, on August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-low breast cancer based on results from the DESTINY-Breast04 trial that demonstrated improved progression-free and overall survival. FDA also gave fam-trastuzumab deruxtecan its fourth approval on August 11, 2022, for unresectable or metastatic HER2-activating non-small cell lung cancer (NSCLC).

    October 07, 2022
    Strategies to Promote Safe Medication Administration Practices
    Chemotherapy

    Strategies to Promote Safe Medication Administration Practices

    Medication administration is a high-risk process that requires critical thinking, efficient decision-making, attention to detail, and a foundational knowledge of basic pharmacology. The process is not a single task but a cascade of events that include handling, ordering, preparing, dispensing, administering, and monitoring. Although nurses’ involvement varies at each phase, the risk for errors always exists, and consequences can have a lifelong impact on patients, families, and healthcare workers. Nurses can use the following strategies in their responsibility as the last line of defense for safe medication administration.

    October 06, 2022
    Eugia US, LLC, Recalls AuroMedics Acyclovir Sodium Injection Because of Particulate Matter
    U.S. Food and Drug Administration (FDA)

    Eugia US, LLC, Recalls AuroMedics Acyclovir Sodium Injection Because of Particulate Matter

    On September 27, 2022, the U.S. Food and Drug Administration reported Eugia US, LLC’s, voluntary recall of AuroMedics acyclovir sodium injection 500 mg per 10 ml (50 mg/ml) single-dose vial to the consumer level because of reported presence of a dark red, brown, and black particulate inside the vial.

    October 03, 2022
    FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma

    On September 30, 2022, the U.S. Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi®) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.

    October 03, 2022
    FDA Approves Selpercatinib for RET Fusion-Positive Non-Small Cell Lung Cancer and Locally Advanced or Metastatic Solid Tumors
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selpercatinib for RET Fusion-Positive Non-Small Cell Lung Cancer and Locally Advanced or Metastatic Solid Tumors

    On September 21, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to selpercatinib (Retevmo®) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion and accelerated approval for adults with locally advanced or metastatic solid tumors with a RET gene fusion that progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

    September 23, 2022
    FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity n Pediatric Patients
    U.S. Food and Drug Administration (FDA)

    FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients

    On September 20, 2022, the U.S. Food and Drug Administration (FDA) approved the use of sodium thiosulfate (Pedmark®) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged 1 month and older with localized, nonmetastatic solid tumors.

    September 22, 2022
    Testicular Cancer Survivors May Need Fewer Monitoring Scans
    Cancer screening

    Testicular Cancer Survivors May Need Fewer Monitoring Scans

    Monitoring early-stage testicular cancer survivors for disease recurrence after surgery using either magnetic resonance imaging or fewer computed tomography scans is just as effective as more frequent intervals, researchers reported in study findings published in the Journal of Clinical Oncology.

    September 21, 2022
    Share Your Best Practices and Other Oncology Nursing Experiences Through an ONS Voice Article or Video
    Clinical practice

    Share Your Best Practices and Other Oncology Nursing Experiences Through an ONS Voice Article or Video

    You and your colleagues innovate every day—providing individual patient cases, developing best practices, and collaborating on other shared experiences. ONS Voice articles and its new video series, My Practice, can help you disseminate your expertise and guidance to other oncology nurses. Tell us your topic ideas, and ONS Publications staff will help you either write an article or create a video resource illustrating your experience.  

    September 19, 2022
    Baxter Healthcare Corporation Recalls Clearlink Basic Solution Set With Duovent Because of Leaks That Risk Exposure to Toxic Substances
    U.S. Food and Drug Administration (FDA)

    Baxter Healthcare Corporation Recalls Clearlink Basic Solution Set With Duovent Because of Leaks That Risk Exposure to Toxic Substances

    On September 15, 2022, the U.S. Food and Drug Administration reported Baxter Healthcare Corporation’s recall of Clearlink basic solution set with Duovent because of reports of leaks. FDA identified it as a class I recall, the most serious type of recall, where use of the set may cause serious injuries or death.

    September 16, 2022
    Oncology Nurses’ Role in Translating Biomarker Testing Results
    Genetics & genomics

    Oncology Nurses’ Role in Translating Biomarker Testing Results

    As oncology biomarker testing becomes a routine part of clinical practice, so does first-line use of their associated targeted therapies such as monoclonal antibodies, checkpoint inhibitors, and tyrosine kinase inhibitors.

    September 15, 2022
    FDA Reports Squamous Cell Carcinoma and Various Lymphomas in Capsule Around Breast Implants
    U.S. Food and Drug Administration (FDA)

    FDA Reports Squamous Cell Carcinoma and Various Lymphomas in Capsule Around Breast Implants

    On September 8, 2022, the U.S. Food and Drug Administration reported that cancers, including squamous cell carcinoma and various lymphomas, may develop in the capsule that forms around breast implants.

    September 12, 2022
    FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer

    On September 2, 2022, the U.S. Food and Drug Administration approved durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer.

    September 07, 2022
    FDA Approves Pemigatinib for Relapsed or Refractory Myeloid or Lymphoid Neoplasms With FGFR1 Rearrangement
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pemigatinib for Relapsed or Refractory Myeloid or Lymphoid Neoplasms With FGFR1 Rearrangement

    On August 26, 2022, the U.S. Food and Drug Administration approved pemigatinib (Pemazyre®) for adults with relapsed or refractory myeloid or lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.

    August 30, 2022
    FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft-Versus-Host Disease, Including a New Oral Suspension
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ibrutinib for Pediatric Patients With Chronic Graft-Versus-Host Disease, Including a New Oral Suspension

    On August 24, 2022, the U.S. Food and Drug Administration approved ibrutinib (Imbruvica®) for pediatric patients aged less than 1 year with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.

    August 25, 2022
    Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Nivolumab and Relatlimab-Rmbw

    When OpdualagTM (nivolumab and relatlimab-rmbw), a fixed-dose combination therapy that consists of two distinct monoclonal antibodies, received FDA approval on March 18, 2022, for the treatment of unresectable or metastatic melanoma for adult and pediatric patients 12 years of age or older, it became the first approved combination therapy that includes two distinct immunotherapy agents in a single infusion. Relatlimab-rmbw is also the first approved lymphocyte activation gene-3–blocking antibody.

    August 23, 2022
    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for HER2-Variant Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for HER2-Variant Non-Small Cell Lung Cancer

    On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2) variants, as detected by an FDA-approved test, and who have received a prior systemic therapy. This is the first drug approved for HER2-variant NSCLC.

    August 15, 2022
    FDA Approves Capmatinib for Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Capmatinib for Metastatic Non-Small Cell Lung Cancer

    On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta®) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

    August 15, 2022
    FDA Publishes Three New Biosimilars Resources for Healthcare Providers
    U.S. Food and Drug Administration (FDA)

    FDA Publishes Three New Biosimilars Resources for Healthcare Providers

    To raise awareness and better educate patients and providers about biosimilars’ potential in clinical care, the U.S. Food and Drug Administration (FDA) added three new fact sheets to its healthcare provider resources in July 2022.

    August 11, 2022
    FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer

    On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa®) tablets in combination with docetaxel for adult patients with metastatic hormone-sensitive prostate cancer.

    August 08, 2022
    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Low Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Low Breast Cancer

    On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for use in adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

    August 08, 2022
    Genetic Disorder Reference Sheet:  Multiple Endocrine Neoplasia Type 2
    Genetics & genomics

    Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2

    Multiple endocrine neoplasia type 2 is an autosomal dominant disease that occurs because of germline pathogenic variants in the rearranged during transfection (RET) proto-oncogene. The RET gene was isolated in 1993 and pathogenic variants affect 1–10 per 100,000 people. Approximately 50% of cases are de novo.

    August 04, 2022
    Legislation and Cancer Care
    Cancer health policy

    Legislation and Cancer Care

    Research and practice changes funded through healthcare legislation have influenced today’s care delivery across all settings: hospitals, clinics, and even homes. And with their constituents laser-focused on health in today’s pandemic society, legislators have never made that happen so quickly.

    August 02, 2022
    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Lutetium Lu 177 Vipivotide Tetraxetan

    After clinical trial results demonstrated a four-month improvement in overall survival compared to best standard care, in March 2022 the U.S. Food and Drug Administration approved lutetium lu 177 vipivotide tetraxetan (PluvictoTM) to treat prostate-specific membrane antigen–expressing metastatic castration-resistant prostate cancer.

    July 26, 2022
    Smiths Medical Recalls Medfusion 3500 and 4000 Syringe Infusion Pumps for Software Malfunctions That Can Affect Infusion Delivery
    U.S. Food and Drug Administration (FDA)

    Smiths Medical Recalls Medfusion 3500 and 4000 Syringe Infusion Pumps for Software Malfunctions That Can Affect Infusion Delivery

    On July 20, 2022, the U.S. Food and Drug Administration (FDA) reported Smiths Medical’s recall of its Medfusion 3500 and 4000 syringe infusion pumps because of software malfunctions. FDA identified it as a class I recall, the most serious type of recall, where use of the devices may cause serious injuries or death.

    July 21, 2022
    What the Evidence Says About Traditional Chinese Medicine for Chronic Diarrhea
    Research

    What the Evidence Says About Traditional Chinese Medicine for Chronic Diarrhea

    Diarrhea is a distressing condition that significantly affects patients’ quality of life and social functioning. Characterized by passage of more than three unformed stools in 24 hours, in cancer it can be caused by chemotherapy, radiotherapy, laxatives and antibiotics, enteral feeding, malabsorption syndromes, colectomy, or several types of malignant tumors. Diarrhea has also been reported in long-term cancer survivors. Standard treatment options such as opiate agonists and adsorbents are associated with side effects that may increase a patient’s symptom burden.

    July 18, 2022
    Oncology Nursing QI Project Shows Normal Saline Is Comparable to Heparin for Pediatric CVCs
    Research

    Oncology Nursing QI Project Shows Normal Saline Is Comparable to Heparin for Pediatric CVCs

    Emerging evidence has consistently shown that flushing central venous catheters with normal saline is comparable to heparin flushes in the adult care setting, leading to updated guideline recommendations that include saline as an alternative. But to date, only two studies have evaluated the two options in pediatric patients, the older of which found increased complications when used in children with leukemia or lymphoma. Is normal saline an acceptable alternative in that population?

    July 12, 2022
    FDA Warns About Risk of Death and Serious Side Effects With Duvelisib
    U.S. Food and Drug Administration (FDA)

    FDA Warns About Risk of Death and Serious Side Effects With Duvelisib

    On June 30, 2022, the U.S. Food and Drug Administration issued a drug safety communication for duvelisib (Copiktra®) after results from a clinical trial showed a possible increased risk of death associated with the agent, which is approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL who have received at least two prior therapies. The clinical trial results also associated duvelisib with a higher risk of serious side effects, including infections, diarrhea, lung and intestinal inflammation, skin reactions, and elevated liver enzymes.

    July 06, 2022
    Self-Affirmations Build Your Personal and Moral Resiliency
    Nurse well-being

    Self-Affirmations Build Your Personal and Moral Resiliency

    Positive phrases or statements that challenge negative or unhelpful thoughts can motivate you, encourage positive lifestyle changes, and boost your self-esteem. Repeat self-affirmation mantras regularly to fully reap the benefits of this practice and make long-term changes to the way you think and feel.

    June 29, 2022
    Healthcare Organizations Advocate for Clinical Trial Diversity in Letter to Congress
    Clinical practice

    Healthcare Organizations Advocate for Clinical Trial Diversity in Letter to Congress

    Healthcare organizations advocated to improve diversity among clinical trials in a letter sent to U.S. Congress in May encouraging the government to take steps as the reauthorization of the Prescription Drug User Fee Act (PDUFA) approaches. The PDUFA allows the U.S. Food and Drug Administration to review and approve drugs, but the authorization is set to expire in September of 2022.

    June 28, 2022
    Support Patients’ Autonomy and Cultural Choices
    Ethics in nursing

    Support Patients’ Autonomy and Cultural Choices

    You are the oncology nurse caring for Maria, who has been diagnosed with non-small cell lung cancer (NSCLC). She says she doesn’t understand how she developed lung cancer because she has always lived a clean lifestyle according to her religious practices. You notice that although Maria is initially conversant with you, she allows her husband to speak for her whenever he is present. When you mention your observation to Maria, she tells you that in her religious culture, medical decisions are deferred to the high elders of the church.

    June 28, 2022
    FDA Says It’s Continuing to Evaluate Pulse Oximeters’ Race-Related Accuracy and Limitations
    U.S. Food and Drug Administration (FDA)

    FDA Says It’s Continuing to Evaluate Pulse Oximeters’ Race-Related Accuracy and Limitations

    More than a year and a half after a report suggesting a potential racial bias in pulse oximeter technology first surfaced as a letter to the editor in the New England Journal of Medicine (NEJM), on June 21, 2022, the U.S. Food and Drug Administration (FDA) said that it is continuing its investigation into the devices’ accuracy and performance, particularly among people of color.

    June 27, 2022
    Genomics’ Red Flag Rule  of Too and Two
    Genetics & genomics

    Genomics’ Red Flag Rule of Too and Two

    I often use mnemonics, a memory tool, to simplify learning. Mnemonics can be any pattern of letters, numbers, words, images, or other relatable associations that help you remember.

    June 27, 2022
    Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Loncastuximab Tesirine-Lpyl

    Based on LOTIS-2 trial results that reported an overall response rate of nearly 50%, in April 2021 the U.S. Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (ZynlontaTM) for adults with relapsed or refractory large B-cell lymphoma.

    June 21, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice

    The Case of the Late Head and Neck Lymphedema

    Samuel, a 55-year-old patient with a history of T3N1M0 oropharyngeal HPV+ cancer on the base of his tongue, underwent surgery followed by 70 Gy of intensity-modulated radiation over seven weeks with concurrent weekly cisplatin. He responded well and had a positron emission tomography (PET) scan three months post-treatment that showed no cancer. Two months later, Samuel calls the triage line to report swelling on the left side of his neck, the same area where he first noticed a lymph node that led to his initial diagnosis.

    June 20, 2022
    Maintain Oral Adherence With ONS Guidelines™
    Research

    Maintain Oral Adherence With ONS Guidelines™

    With so many of today’s cancer treatments administered orally, ensuring that patients adhere to their regimen as prescribed is essential to optimal outcomes. According to the World Health Organization, medication adherence is the single most important modifiable factor that affects treatment outcomes.

    June 14, 2022
    Pediatric Patients With Cancer Are Vulnerable to Sleep Disturbance
    Patient quality of life

    Pediatric Patients With Cancer Are Vulnerable to Sleep Disturbance

    Sleep disturbance has a significant impact on quality of life, including mental and physical health and academic, cognitive, and social functioning. It is one of the most common symptoms reported by pediatric patients with cancer and is significantly related to neurocognitive function for survivors.

    June 13, 2022
    FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension

    On June 8, 2022, the U.S. Food and Drug Administration (FDA) reported Plastikon Healthcare's voluntarily recall of one lot of Milk of Magnesia 2,400 mg/10 ml oral suspension, one lot of Milk of Magnesia 2,400 mg/30 ml oral suspension, 11 lots of magnesium hydroxide 1,200 mg/aluminum hydroxide 1,200 mg/simethicone 120 mg per 30 ml oral suspension, and two lots of magnesium hydroxide 2,400 mg/aluminum hydroxide 2,400 mg/simethicone 240 mg per 30 ml oral suspension to the consumer level because of microbial contamination.

    June 10, 2022
    Independent Advocates Help Patients With Dementia Navigate Cancer Care
    Care coordination

    Independent Advocates Help Patients With Dementia Navigate Cancer Care

    Clinicians have an implicit—if not explicit—obligation to advocate for their patients. However, as health care’s complexity increases, independent advocates can help patients navigate systematic challenges throughout the continuum. Independent advocates follow the patient, not the reimbursement constraints, a chief distinction between us and clinical, facility, or agency case managers.

    June 09, 2022
    Childhood Cancer Survivors Have Healthy but Riskier Pregnancies
    Cancer research

    Childhood Cancer Survivors Have Healthy but Riskier Pregnancies

    Babies born to adult survivors of childhood cancers are as healthy as those born to adults without a history of cancer, but survivors have a higher risk of severe complications during pregnancy, researchers reported in the Journal of the National Cancer Institute.

    June 08, 2022
    Special Populations
    Cancer health disparities

    Special Populations

    Various patient groups, including children, racial and ethnic minorities, and low-income populations, may need more specialized healthcare services than others, particularly during a cancer journey.

    June 07, 2022
    FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks
    U.S. Food and Drug Administration (FDA)

    FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks

    On June 2, 2022, the U.S. Food and Drug Administration (FDA) reported a cybersecurity vulnerability that affects software in the Illumina NextSeq 550Dx, MiSeqDx, NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq next generation sequencing instruments. The devices are used in diagnostic (Dx), research-use only (RUO), or dual boot (either Dx or RUO) modes. 

    June 03, 2022
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    Oncology nurse-patient relationship

    Connect With Your Patients on a Human Level as Well as a Healthcare Level

    As a healthcare provider, I had been warned about getting too close to my patients. They told me that it was unprofessional, it would cloud my judgment, it would lead to emotional burnout, and various other reasons. For my first year as a nurse, I took that advice to heart and kept my emotional distance while still doing my best to provide care to the whole patient. Then one night I met Jeff, and everything changed.

    June 03, 2022
    FDA Withdraws Approval of Umbralisib Because of Safety Concerns
    U.S. Food and Drug Administration (FDA)

    FDA Withdraws Approval of Umbralisib Because of Safety Concerns

    Because of safety concerns, the U.S. Food and Drug Administration (FDA) withdrew its approval of umbralisib (Ukoniq®) on June 1, 2022. Umbralisib had been approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).

    June 02, 2022
    FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

    On May 27, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tisagenlecleucel (Kymriah®) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

    June 02, 2022
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲